Facies and evolution of the carbonate factory during the Permian–Triassic crisis in South Tibet, China

The nature of Phanerozoic carbonate factories is strongly controlled by the composition of carbonate-producing faunas. During the Permian–Triassic mass extinction interval there was a major change in tropical shallow platform facies: Upper Permian bioclastic limestones are characterized by benthic communities with significant richness, for example, calcareous algae, fusulinids, brachiopods, corals, molluscs and sponges, while lowermost Triassic carbonates shift to dolomicrite-dominated and bacteria-dominated microbialites in the immediate aftermath of the Permian–Triassic mass extinction. However, the spatial–temporal pattern of carbonates distribution in high latitude regions in response to the Permian–Triassic mass extinction has received little attention. Facies and evolutionary patterns of a carbonate factory from the northern margin of peri-Gondwana (palaeolatitude ca 40°S) are presented here based on four Permian–Triassic boundary sections that span proximal, inner to distal, and outer ramp settings from South Tibet. The results show that a cool-water bryozoan-dominated and echinoderm-dominated carbonate ramp developed in the Late Permian in South Tibet. This was replaced abruptly, immediately after the Permian–Triassic mass extinction, by a benthic automicrite factory with minor amounts of calcifying metazoans developed in an inner/middle ramp setting, accompanied by transient subaerial exposure. Subsequently, an extensive homoclinal carbonate ramp developed in South Tibet in the Early Triassic, which mainly consists of homogenous dolomitic lime mudstone/wackestone that lacks evidence of metazoan frame-builders. The sudden transition from a cool-water, heterozoan dominated carbonate ramp to a warm-water, metazoan-free, homoclinal carbonate ramp following the Permian–Triassic mass extinction was the result of the combination of the loss of metazoan reef/mound builders, rapid sea-level changes across Permian–Triassic mass extinction and profound global warming during the Early Triassic

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.</p

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol�which is a marker of cardiovascular risk�changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95 credible interval 3.7 million�4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world. © 2020, The Author(s), under exclusive licence to Springer Nature Limited